Evidence map›Paper›PMID 40411418›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

The CRL7

Simone Sabbioni, Maria Grazia Filippone, Letizia Amadori, Stefano Confalonieri, Roberta Bonfanti, Stefano Capoano, Ivan Nicola Colaluca, Stefano Freddi, Giovanni Bertalot, Giovanni Fagà and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Endocytic Control of Cell-Autonomous and Non-Cell-Autonomous Functions of p53.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. The CRL7Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. F-box in breast cancer: mechanism of action and therapeutic potential.American journal of translational research · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Simone SabbioniIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Maria Grazia FilipponeIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Letizia AmadoriIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Stefano ConfalonieriIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Roberta BonfantiIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Stefano CapoanoIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Ivan Nicola ColalucaIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Stefano FreddiIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Giovanni BertalotIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Giovanni FagàIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Elisa ZagarríIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Mario VarasiIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Rosalind Helen GunbyIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Ciro MercurioIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Salvatore PeceIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.
Pier Paolo Di FioreIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.ORCID https://orcid.org/0000-0002-2252-0950
Daniela TosoniIEO, European Institute of Oncology IRCCS, Milan, 20139, Italy.

Funding

Fondazione AIRC per la ricerca sul cancro ETS 5x1000 MCO 10.000Fondazione AIRC per la ricerca sul cancro ETS IG15538Fondazione AIRC per la ricerca sul cancro ETS IG23049Fondazione AIRC per la ricerca sul cancro ETS IG23060Ministero della Salute PNRR-MCNT2-2023-12378490Ministero della Salute RF-2016-02361540Ministero della Salute RF-2021-12373957Ministero della Salute Ricerca-corrente-and-5xMille-fundsMinistero dell'Istruzione, dell'Università e della Ricerca PNRRCN00000041Ministero dell'Istruzione, dell'Università e della Ricerca PRIN2017Ministero dell'Istruzione, dell'Università e della Ricerca PRIN2020
6 · The paper itself

Abstract

NUMB is a tumor suppressor gene that functions by inhibiting the action of the NOTCH proto-oncogene and enhancing the levels and activity of the tumor suppressor protein p53. In breast cancer (BC), NUMB loss of function (LOF), mediated by various molecular mechanisms, is a frequent and causal event. Herein, it is established that loss of NUMB protein, resulting from protein hyper-degradation, is the prevalent mechanism of NUMB LOF in BC. Through an RNAi-based screening, the CRL7

Indexed as

Breast NeoplasmsMembrane ProteinsNeoplastic Stem CellsNerve Tissue ProteinsAnimalsCell Line, TumorFemaleHumansMiceProto-Oncogene MasMAS1 protein, humanMembrane ProteinsNerve Tissue ProteinsNUMB protein, humanProto-Oncogene Masbreast cancercancer stem cellsCRL7FBXW8 complexNUMBproteasomal degradation

Identifiers

PMID40411418
PMCPMC12224932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.